Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$6.25 USD
-0.36 (-5.45%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $6.33 +0.08 (1.28%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Foghorn Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 34 | 19 | 1 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 34 | 19 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 142 | 136 | 102 | 69 | 51 |
Income After Depreciation & Amortization | -108 | -117 | -101 | -69 | -51 |
Non-Operating Income | 14 | 8 | 1 | 1 | 1 |
Interest Expense | 0 | 0 | 2 | 1 | 1 |
Pretax Income | -94 | -109 | -101 | -69 | -51 |
Income Taxes | 4 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -98 | -109 | -101 | -69 | -51 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -98 | -109 | -101 | -69 | -51 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -107 | -115 | -97 | -67 | -50 |
Depreciation & Amortization (Cash Flow) | 1 | 2 | 3 | 1 | 1 |
Income After Depreciation & Amortization | -108 | -117 | -101 | -69 | -51 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 41.98 | 41.59 | 37.17 | 11.05 | NA |
Diluted EPS Before Non-Recurring Items | -2.34 | -2.62 | -2.73 | -6.23 | NA |
Diluted Net EPS (GAAP) | -2.34 | -2.62 | -2.73 | -6.23 | NA |
Fiscal Year end for Foghorn Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 5.05 | 5.77 | 17.48 | 5.60 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 5.05 | 5.77 | 17.48 | 5.60 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 33.24 | 31.23 | 34.56 | 37.65 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -28.19 | -25.46 | -17.08 | -32.05 |
Non-Operating Income | NA | 3.18 | 3.34 | 3.47 | 3.51 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -25.02 | -22.12 | -13.61 | -28.55 |
Income Taxes | NA | 0.00 | 1.99 | 0.74 | 0.94 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -25.02 | -24.11 | -14.35 | -29.49 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -25.02 | -24.11 | -14.35 | -29.49 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 42.43 | 41.98 | 42.03 | 41.83 |
Diluted EPS Before Non-Recurring Items | NA | -0.59 | -0.57 | -0.34 | -0.70 |
Diluted Net EPS (GAAP) | NA | -0.59 | -0.57 | -0.34 | -0.70 |